Clinicopathologic characteristics, laboratory parameters, treatment protocols, and outcomes of pancreatic cancer: A retrospective cohort study of 1433 patients in China

Objectives: The prognosis of people with pancreatic cancer is extremely unfavorable. However, the prognostic factors remain largely undefined.We aimed to perform comprehensive analyses of clinicopathologic characteristics, laboratory parameters, and treatment protocols for exploring their role as prognostic factors of pancreatic cancer. Methods: Patients diagnosed with pancreatic cancer and hospitalized at the China National Cancer Center between April 2006 and May 2016 were enrolled in this retrospective cohort study. Clinicopathologic characteristics, laboratory parameters, and treatment protocols were compared among patients at different stages of the disease. The association between these factors and overall survival (OS) was analyzed using the Kaplan-Meier method and Cox proportional hazards model. Results: The present study included 1,433 consecutive patients with pancreatic cancer. Median OS was 10.6months (95%confidence interval [CI] 9.8-11.3months), with 1-, 3-, and 5-year survival rates of 43.7%, 14.8%, and 8.8%, respectively. Cox multivariate analysis findings identified the following factors as independent predictors of OS: gender (female vsmale, hazard ratio 0.72, 95% CI [0.54-0.95]); elevated total bilirubin (TBil; 1.82, 1.34-2.47); elevated carbohydrate antigen 19-9 (CA19-9; 1.72, 1.17-2.54); tumor being located in pancreatic body and tail (1.52, 1.10-2.10); advanced T stage (T3-4 vs T1-2, 1.62, 1.15-2.27); lymph node metastasis (1.57, 1.20-2.07); distant metastasis (1.59, 1.12-2.27); the presence of surgical resection (0.53, 0.34-0.81); and the presence of systemic chemotherapy (0.62, 0.45-0.82). Conclusions: Being male, elevated TBil and carcinoembryonic antigen, tumor being located in pancreatic body and tail, advanced T stage, lymph node and distant metastasis, the absence of surgical resection, and the absence of systematic chemotherapy were associated with worse OS in patients with pancreatic cancer.